Aegis Maintains Buy on Valeant (VRX); One-Time Items Don't Reflect True Operations
Tweet Send to a Friend
Aegis Capital maintains a Buy rating and $140 price target on Valeant Pharmaceuticals (NYSE: VRX) following Q3 results issued earlier ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
